Adalimumab (Anti-Human TNF-alpha, Human Antibody) |
| Katalog-Nr.GC34214 |
Adalimumab (Anti-Human TNF-alpha, Human Antibody) ist eine der führenden Therapien zur Behandlung von rheumatoider Arthritis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 331731-18-1
Sample solution is provided at 25 µL, 10mM.
Adalimumab (Anti-Human TNF-alpha, Human Antibody) ist eine der führenden Therapien zur Behandlung von rheumatoider Arthritis. Es handelt sich um einen humanisierten monoklonalen Antikörper, der an TNF-α bindet und dessen Interaktion mit dem TNF-Rezeptor blockiert[1]. Es neutralisiert sowohl lösliches als auch membrangebundenes TNF-α[2].
Adalimumab (Anti-Human-TNF-alpha, Human Antibody) verhindert die wesentlichen entzündlichen Auswirkungen von TNF-α auf die Endothelaktivierung, die Adhäsion von Endothel-Monozyten und die Endothel-Leckage[3].
Adalimumab (Anti-Human-TNF-alpha, Human Antibody) verhinderte die Hochregulierung von TNF-α, verringerte den Tod von Photorezeptorzellen, verlangsamte die Aktivierung von Mikroglia- und Müller-Zellen, verbesserte die antioxidative Reaktion und milderte die energetische und metabolische Dysfunktion bei P18[4]. VaD-Ratten, die mit Adalimumab (Anti-Human-TNF-alpha, Human Antibody) behandelt wurden, zeigten signifikante Verbesserungen im Gedächtnis. Darüber hinaus linderte die Behandlung mit Adalimumab (Anti-Human-TNF-alpha, Human Antibody) signifikant den Neuronenverlust im Hippocampus von VaD-Ratten[5]. Die wichtige Rolle von TNF-α für die Entwicklung atherosklerotischer Plaques in experimentellen Modellen ist gut dokumentiert; verschiedene TNF-α-defiziente Mausmodelle zeigten durchgehend eine verringerte Plaquebildung[6,7]. Adalimumab (Anti-Human-TNF-alpha, Human Antibody) hat bei rheumatoider Arthritis eine gute Prognose und Verbesserung der körperlichen Funktion gezeigt[8].
References:
[1]. HÜrlimann D, Forster A, et,al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002 Oct 22;106(17):2184-7. doi: 10.1161/01.cir.0000037521.71373.44. PMID: 12390945.
[2]. Ternant D, Ducourau E, et,al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. doi: 10.1111/bcp.12509. PMID: 25223394; PMCID: PMC4309634.
[3]. Oberoi R, Schuett J, et,al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. doi: 10.1371/journal.pone.0160145. PMID: 27467817; PMCID: PMC4965117.
[4]. MartÍnez-FernÁndez de la CÁmara C, HernÁndez-Pinto AM, et,al. Adalimumab Reduces Photoreceptor Cell Death in A Mouse Model of Retinal Degeneration. Sci Rep. 2015 Jul 14;5:11764. doi: 10.1038/srep11764. PMID: 26170250; PMCID: PMC4501000.
[5]. Xu JJ, Guo S, et,al. Adalimumab ameliorates memory impairments and neuroinflammation in chronic cerebral hypoperfusion rats. Aging (Albany NY). 2021 May 24;13(10):14001-14014. doi: 10.18632/aging.203009. Epub 2021 May 24. PMID: 34030135; PMCID: PMC8202885.
[6]. BrÅnÉn L, Hovgaard L, et,al. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42. doi: 10.1161/01.ATV.0000143933.20616.1b. Epub 2004 Sep 2. PMID: 15345516.
[7]. Ohta H, Wada H, et,al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005 May;180(1):11-7. doi: 10.1016/j.atherosclerosis.2004.11.016. Epub 2005 Jan 20. PMID: 15823270.
[8]. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother. 2007 Sep;8(13):2089-107. doi: 10.1517/14656566.8.13.2089. PMID: 17714062.
| Pharmacokinetic experiment [1]: | |
|
Preparation Method |
Using double-antigen enzyme-linked immunosorbent TNF-¦Á Adalimumab -coated plates and their detection by peroxidase-conjugated IgG. |
|
Reaction Conditions |
These patients received 40 mg adalimumab subcutaneously every other week combined with methotrexate and follow-up was done for 1 year. |
|
Applications |
Thirty patients treated for RA were analysed. The following pharmacokinetic and PK-PD parameters were estimated (interidividual coefficient of variation): apparent volume of distribution (Vd /F) = 10.8 l (92%); apparent clearance (CL/F) = 0.32 l day(-1) (17%); first-order absorption rate (ka ) = 0.28 day(-1) ; CRP input (kin ) = 22.0 mg l(-1) day(-1) (65%); adalimumab concentration leading to a 50% decrease in kin (C50 ) = 3.6 mg l(-1) (88%); baseline DAS28 (DAS0 ) = 5.5 mg l(-1) (11%); and adalimumab concentration leading to 50% decrease of DAS0 (IC50 ) = 11.0 mg l(-1) (71%). Simulations showed that a 160 mg loading dose should reduce the time to reach efficacy in terms of both CRP and DAS28 after the first injection. |
| Cell experiment [2]: | |
|
Cell lines |
THP-1 monocytes |
|
Preparation Method |
CellTracker green-labelled THP-1 monocytes on a HUVECs monolayer after incubation with conditioned media from oxLDL-stimulated THP-1 macrophages (oxLDL CM) with or without adalimumab (ada) for 4 hours followed by the addition of CellTracker green-labelled THP-1 monocytes. |
|
Reaction Conditions |
1 ¦̧/mL Adalimumab (Anti-Human TNF-alpha, Human Antibody) for 4 hours |
|
Applications |
The TNF-¦Á inhibitor adalimumab suppresses adhesion of THP-1 monocytes to endothelial cells. |
| Animal experiment [3]: | |
|
Animal models |
Rd10 mice |
|
Preparation Method |
To evaluate the effect of Adalimumab (Anti-Human TNF-alpha, Human Antibody), each rd10 mouse received one intraperitoneal injection of Adalimumab (Anti-Human TNF-alpha, Human Antibody) aline solution at 3 mg/kg every three days starting at P9 and until P17. |
|
Dosage form |
3 mg/kg Adalimumab (Anti-Human TNF-alpha, Human Antibody)every three days |
|
Applications |
intraperitoneal administration of Adalimumab (Anti-Human TNF-alpha, Human Antibody) significantly decreased the number of TUNEL-positive cells in the ONL at P18 (2.7 ± 0.4 TUNEL-positive cells) compared to vehicle-treated rd10 retinas (12.5 ± 2.4 TUNEL-positive cells) |
|
References: |
|
| Cas No. | 331731-18-1 | SDF | |
| Canonical SMILES | [Adalimumab] | ||
| Formula | LU200134, D2E7 | M.Wt | 145425.42 |
| Löslichkeit | Storage | Store at -80°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.0069 mL | 0.0344 mL | 0.0688 mL |
| 5 mM | 0.0014 mL | 0.0069 mL | 0.0138 mL |
| 10 mM | 0.0007 mL | 0.0034 mL | 0.0069 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *